Download PDF
Open Access
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(11): 756-759
DOI: 10.1590/0004-282X20180121
Article

Grade I meningiomas with atypical characteristics: a worse prognosis

Meningiomas grau I com características atípicas: um pior prognóstico

Authors

  • Débora S. Marcos

    1   Universidade Federal de São Paulo, Faculdade Paulista de Medicina, Departamento de Patologia, São Paulo SP, Brasil;

  • Manoel A. Paiva Neto

    2   Universidade Federal de São Paulo, Faculdade Paulista de Medicina, Departamento de Neurocirurgia, São Paulo SP, Brasil.

  • Pedro Góes

    2   Universidade Federal de São Paulo, Faculdade Paulista de Medicina, Departamento de Neurocirurgia, São Paulo SP, Brasil.

  • Celina T. F. Oshima

    1   Universidade Federal de São Paulo, Faculdade Paulista de Medicina, Departamento de Patologia, São Paulo SP, Brasil;

  • Marcelo S. Silva

    1   Universidade Federal de São Paulo, Faculdade Paulista de Medicina, Departamento de Patologia, São Paulo SP, Brasil;

  • João N. Stávale

    1   Universidade Federal de São Paulo, Faculdade Paulista de Medicina, Departamento de Patologia, São Paulo SP, Brasil;
Further Information
Also available at
  Permissions and Reprints
Preview

ABSTRACT

The study reviewed the histology of cases of grade I meningiomas with spontaneous necrosis, grade I without necrosis and grade II meningiomas, to evaluate the histological and immunohistochemical factors of the patients’ prognosis, while correlating the clinicopathological features with the clinical follow-up of the patients. A review of 47 cases from the Department of Pathology of UNIFESP was performed and the samples were submitted to immunohistochemical examination with the p53 protein, Ki-67 cell proliferation factor and progesterone receptor markers. A greater expression was found in the progression of several degrees of aggressiveness for p53 and Ki-67, and a higher frequency of progesterone receptors in the lower degrees. The group of grade I meningiomas with spontaneous necrosis showed histological and immunohistochemical indexes that approximate those of the grade II meningioma. This suggests a worse prognosis for grade I meningiomas with necrosis.

RESUMO

O objetivo do estudo foi realizar a revisão histológica de casos de meningiomas grau I com necrose espontânea, grau I sem necrose e grau II para avaliar os fatores histológicos e imunohistoquímicos de prognóstico dos pacientes, correlacionando informações no âmbito clínico-patológico com o seguimento clínico dos pacientes. Foi realizada revisão de 47 casos do Departamento de Patologia da UNIFESP e as amostras foram submetidas a exame imunohistoquímico com os marcadores proteína p53, fator de proliferação celular Ki-67 e receptor de progesterona. Verificou-se maior expressão na progressão dos diversos graus de agressividade para p53 e Ki-67 e maior frequência de receptores de progesterona nos menores graus. O grupo dos meningiomas grau I com necrose espontânea apresentou índices histológicos e imuno-histoquímicos que se aproximam dos meningiomas grau II. Isto sugere um pior prognóstico dos meningiomas grau I com necrose.

Keywords:

meningioma - immunohistochemistry - prognosis - necrosis

Palavras-chave:

meningioma - imuno-histoquímica - prognóstico - necrose


Publication History

Received: 24 April 2018

Accepted: 16 August 2018

Article published online:
22 August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Louis DN, Ohgaki H, Wiestler OD, Webster KC. Louis DN, Ohgaki H et al., editors. WHO classification of tumours of the central nervous system. 4th edition. Lyon: IARC; 2016.
  • 2 Sun SQ, Cai C, Murphy RK, DeWees T, Dacey RG, Grubb RL et al. Management of atypical cranial meningiomas. Part 2: predictors of progression and the role of adjuvant radiation after subtotal resection. Neurosurgery. 2014 Oct;75(4):356-63. https://doi.org/10.1227/NEU.20180121201801210462
  • 3 Muz B, Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015 Dec;3:83-92. https://doi.org/10.2147/HP.S93413
  • 4 Perry A, Brat D, editors. Practical surgical neuropathology. In: Perry A, Brat D., 2nd edition. Philadelphia: Churchill Livingstone; 2010. Astrocytic and oligodendroglial tumors, p. 98-105.
  • 5 Shayanfar N, Mashayekh M, Mohammadpour M. Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma. Acta Med Iran. 2010 May-Jun;48(3):142-7.
  • 6 Roser F, Samii M, Ostertag H, Bellinzona M. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir (Wien). 2004 Jan;146(1):37-44. https://doi.org/10.1007/s00701-003-0173-4
  • 7 Bénard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat. 2003 Mar;21(3):182-91. https://doi.org/10.1002/humu.10172
  • 8 Backer-Grøndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol. 2012;5(3):231-42.
  • 9 Pavelin S, Becic K, Forempoher G, Mrklic I, Pogorelic Z, Titlic M et al. Expression of Ki-67 and p53 in meningiomas. Neoplasma. 2013;60(5):480-5. https://doi.org/10.4149/neo_2013_062
  • 10 Jenkinson MD, Weber DC, Haylock BJ, Mallucci CL, Zakaria R, Javadpour M. Atypical meningoma: current management dilemmas and prospective clinical trials. J Neurooncol. 2015 Jan;121(1):1-7. https://doi.org/10.1007/s11060-014-1620-1
  • 11 Backer-Grøndahl T, Moen BH, Sundstrøm SH, Torp SH. Histopathology and prognosis in human meningiomas. APMIS. 2014 Sep;122(9):856-66. https://doi.org/10.1111/apm.12248
  • 12 Cho H, Ha SY, Park SH, Park K, Chae YS. Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. J Korean Med Sci. 1999 Apr;14(2):199-205. https://doi.org/10.3346/jkms.1999.14.2.199
  • 13 Telugu RB, Chowhan AK, Rukmangadha N, Patnayak R, Phaneendra BV, Prasad BC et al. Histopathological and immunohistochemical evaluation of meningiomas with reference to proliferative markers p53 and Ki-67. J Clin Diagn Res. 2016 Jan;10(1):EC15-9. https://doi.org/10.7860/JCDR/2016/15661.7117
  • 14 Fakhrjou A, Meshkini A, Shadrvan S. Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas. Pak J Biol Sci. 2012 Jun;15(11):530-5. https://doi.org/10.3923/pjbs.2012.530.535
  • 15 Kumar S, Kakkar A, Suri V, Kumar A, Bhagat U, Sharma MC et al. Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: adjuncts to histopathological grading and predictors of aggressive behavior. Neurol India. 2014 Jul-Aug;62(4):376-82. https://doi.org/10.4103/0028-3886.141248